Daiichi Sankyo Soars After Breakthrough Cancer Drug Approval

In a significant development that has captured the attention of investors and the medical community alike, shares of Daiichi Sankyo Co., a prominent Japanese pharmaceutical firm, have experienced a remarkable surge, marking their most substantial single-day gain in over five months. This upswing followed the groundbreaking approval of its innovative cancer treatment, which promises to offer new hope for patients battling specific forms of cancer.

Continue reading